Close Menu

Tekmira

Alnylam Pharmaceuticals this week released new preclinical data on its GalNAc conjugate delivery technology, showing that the approach could permit subcutaneous delivery of siRNAs with a wide therapeutic index.

This article has been updated to include additional stock information and analyst comment.

Title: Compositions and Methods for siRNA Inhibition of HIF-1 Alpha
Patent Number: 8,236,775
Filed: Dec. 3, 2009
Lead Inventor: Samuel Reich, University of Pennsylvania (Opko Health)

Title: Enhancement of Influenza Gene Expression
Patent Number: 8,227,188
Filed: Sept. 3, 2010
Lead Inventor: Antonin de Fougerolles, Alnylam Pharmaceuticals

Alnylam Pharmaceuticals this week released positive phase I data on its investigational TTR-mediated amyloidosis treatment ALN-TTR02, reporting that the drug triggered up to 94 percent reductions in levels of its target protein after a single dose.

Title: Reversible siRNA-Based Silencing Mutant and Endogenous Wild-Type Huntingtin Gene and Its Application for the Treatment of Huntington's Disease
Patent Number: 8,217,018
Filed: June 18, 2008

Tekmira Pharmaceuticals' CEO this week provided an update on the company's ongoing litigation with partner Alnylam Pharmaceuticals, confirming that a roughly one-year-old technology-misappropriation lawsuit could be resolved before the end of 2012.

Alnylam Pharmaceuticals this week announced that the US Patent and Trademark Office has upheld certain claims within a company patent covering the use of siRNAs against kinesin spindle protein, the target of the company's phase I liver cancer drug ALN-VSP.

Pages

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.

A new paper says an effort to introduce gene drives into mosquitos altered the genetic makeup of the local mosquitos, but the company behind the project says the paper is flawed.

Virginia's Department of Forensic Science is offering attorneys a course on DNA testing, the Virginian-Pilot reports.